ESC Premium Access

Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus

Congress Session

About the speaker

Doctor Dimitrios Patoulias

Hippokration General Hospital of Thessloniki, Thessaloniki (Greece)
0 follower

57 more presentations in this session

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Speaker: Doctor J. Borovac (Split, HR)

Thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Speaker: Doctor A. KANWAL (Valhalla, US)

Thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Speaker: Doctor K. Dzaurova (Moscow, RU)

Thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Access the full session

Pharmacology and pharmacotherapy e-posters

Speakers: Doctor D. Patoulias, Doctor J. Borovac, Doctor A. KANWAL, Doctor K. Dzaurova, Mrs A. Boulmpou...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure

27 August 2021

ESC Premium Access

STROKESTOP: Cost-effectiveness of population screening for atrial fibrillation based on long-term follow-up data

27 August 2021

ESC Premium Access

Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

27 August 2021

This platform is supported by

logo Novo Nordisk